Jump to content

List of therapeutic monoclonal antibodies

From Wikipedia, the free encyclopedia

Therapeutic, diagnostic and preventive monoclonal antibodies are clones of a single parent cell. When used as drugs, the International Nonproprietary Names (INNs) end in -mab. The remaining syllables of the INNs, as well as the column Source, are explained in Nomenclature of monoclonal antibodies.

Types of monoclonal antibodies with other structures than naturally occurring antibodies.

The abbreviations in the column Type are as follows:

This list of over 500 monoclonal antibodies includes approved and investigational drugs as well as drugs that have been withdrawn from market; consequently, the column Use does not necessarily indicate clinical usage. See the list of FDA-approved therapeutic monoclonal antibodies in the monoclonal antibody therapy page.

This is a dynamic list and may never be able to satisfy particular standards for completeness. You can help by adding missing items with reliable sources.
Name Brand name Type Source Target Approved Use
3F8 mab mouse GD2 ganglioside neuroblastoma
Abagovomab[1] mab mouse CA-125 (imitation) ovarian cancer
Abciximab[2] ReoPro Fab chimeric CD41 (integrin alpha-IIb) Y[3] platelet aggregation inhibitor
Abituzumab[4] mab humanized CD51 cancer
Abrezekimab[5] Fab humanized IL-13
Abrilumab[6] mab human integrin α4 β7 inflammatory bowel disease, ulcerative colitis, Crohn's disease
Actoxumab[6] mab human Clostridioides difficile Clostridioides difficile colitis
Adalimumab[7] Humira mab human TNF-α Y[8] rheumatoid arthritis, Crohn's disease, plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, juvenile idiopathic arthritis, hemolytic disease of the newborn
Adecatumumab[9] mab human EpCAM prostate and breast cancer
Aducanumab[10] Aduhelm mab human Amyloid beta Y[11] Alzheimer's disease
Afasevikumab[12] mab human IL-17A, IL-17F multiple sclerosis
Afelimomab[2] F(ab')2 mouse TNF-α sepsis
Alacizumab pegol[13] F(ab')2 humanized VEGFR2 cancer
Alemtuzumab[14] Lemtrada, Campath mab humanized CD52 Y multiple sclerosis
Alirocumab[15] Praluent mab human PCSK9 Y hypercholesterolemia
Altumomab pentetate Hybri-ceaker mab mouse Carcinoembryonic antigen (CEA) colorectal cancer (diagnosis)
Amatuximab[16] mab chimeric mesothelin cancer
Amivantamab Rybrevant BsAb human Epidermal growth factor receptor (EGFR), cMet Y non-small cell lung cancer
Anatumomab mafenatox[17] Fab mouse Tumor-associated glycoprotein 72 (TAG-72) non-small cell lung cancer
Andecaliximab[18] mab chimeric gelatinase B gastric cancer or gastroesophageal junction adenocarcinoma
Anetumab ravtansine[4] mab human mesothelin (MSLN) cancer
Anifrolumab[4] Saphnelo mab human IFN-α/β receptor Y[19] systemic lupus erythematosus
Ansuvimab Ebanga mab human Ebola virus glycoprotein Y treatment of Zaire ebolavirus (Ebola virus)
Anrukinzumab[13]
(= IMA-638)[20]		 mab humanized IL-13 asthma
Apolizumab[21] mab humanized HLA-DR hematological cancers
Aprutumab ixadotin[22] mab human FGFR2
Arcitumomab[23] CEA-Scan Fab' mouse Carcinoembryonic antigen (CEA) gastrointestinal cancers (diagnosis)
Ascrinvacumab[12] mab human activin receptor-like kinase 1 cancer
Aselizumab[24] mab humanized L-selectin (CD62L) severely injured patients
Atezolizumab[25] Tecentriq mab humanized PD-L1 Y cancer
Atidortoxumab[26] mab human Staphylococcus aureus alpha toxin
Atinumab[16] mab human RTN4
Atoltivimab mab human Ebola virus glycoprotein part of Atoltivimab/maftivimab/odesivimab for treatment of Zaire ebolavirus (Ebola virus)
Atoltivimab/maftivimab/odesivimab Inmazeb mab human Y treatment of Zaire ebolavirus (Ebola virus)
Atorolimumab[2] mab human Rhesus factor hemolytic disease of the newborn[citation needed]
Avelumab[12] Bavencio mab human PD-L1 Y cancer
Axatilimab[27] Niktimvo mab humanized CSF1R Y chronic graft-versus-host disease
Azintuxizumab vedotin[28] mab chimeric/
humanized		 CD319 cancer
Bamlanivimab[29] mab human spike protein receptor binding domain (RBD) of SARS-CoV-2 Emergency Use Authorization (EUA) when used with etesevimab[30] COVID-19
Bapineuzumab[31] mab humanized β-amyloid Alzheimer's disease
Basiliximab[32] Simulect mab chimeric CD25 (α chain of IL-2 receptor) Y prevention of organ transplant rejections
Bavituximab[1] mab chimeric phosphatidylserine cancer, viral infections
BCD-100 human PD-1 melanoma
Bebtelovimab[33] mab human spike protein receptor binding domain (RBD) of SARS-CoV-2 Emergency Use Authorization (EUA)[34] COVID-19
Bectumomab[32] LymphoScan Fab' mouse CD22 non-Hodgkin's lymphoma (detection)
Bedinvetmab[35] Librela[36] mab veterinary nerve growth factor (NGF)[36] Y pain associated with osteoarthritis in dogs[36]
Begelomab[6] mab mouse DPP4
Belantamab mafodotin[5] Blenrep mab humanized B-cell maturation antigen (BCMA) Y (Withdrawn) relapsed or refractory multiple myeloma
Belimumab[37] Benlysta mab human B-cell activating factor (BAFF) Y systemic lupus erythematosus without renal or CNS involvement
Bemarituzumab[26] mab humanized FGFR2 gastric cancer or gastroesophageal junction adenocarcinoma
Benralizumab[38] Fasenra mab humanized CD125 Y asthma
Berlimatoxumab[26] mab human Staphylococcus aureus bi-component leukocidin
Bermekimab[32] Xilonix mab human IL-1α colorectal cancer
Bersanlimab[5] mab human ICAM-1
Bertilimumab[24] mab human CCL11 (eotaxin-1) severe allergic disorders
Besilesomab[39] Scintimun mab mouse Carcinoembryonic antigen (CEA)-related antigen inflammatory lesions and metastases (detection)
Bevacizumab[14] Avastin mab humanized VEGF-A Y metastatic cancer, retinopathy of prematurity
Bezlotoxumab[32] Zinplava mab human Clostridioides difficile Y Clostridioides difficile colitis
Biciromab[32] FibriScint Fab' mouse fibrin II, beta chain thromboembolism (diagnosis)
Bimagrumab[40] mab human ACVR2B myostatin inhibitor
Bimekizumab[10] Bimzelx mab humanized IL-17A, IL-17F, IL-17AF Y psoriasis
Birtamimab mab chimeric serum amyloid A protein amyloidosis
Bivatuzumab[32] mab humanized CD44 v6 squamous cell carcinoma
Bleselumab[12] mab human CD40 organ transplant rejection
Blinatumomab[32] Blincyto BiTE mouse CD19 Y pre-B Acute lymphoblastic leukemia (ALL) (CD19+)
Blontuvetmab[41] Blontress mab veterinary CD20
Blosozumab[42] mab humanized SOST osteoporosis
Bococizumab[32] mab humanized PCSK9 dyslipidemia
Brazikumab[18] mab human IL-23 Crohn's disease
Brentuximab vedotin[32] Adcentris mab chimeric CD30 (TNFRSF8) Y Hodgkin's lymphoma, anaplastic large-cell lymphoma
Briakinumab[32] mab human IL-12, IL-23 psoriasis, rheumatoid arthritis, inflammatory bowel diseases, multiple sclerosis
Brodalumab[42] Siliq mab human IL-17 Y Plaque psoriasis
Brolucizumab[25] Beovu scFv humanized vascular endothelial growth factor A (VEGFA) Y wet age-related macular degeneration
Brontictuzumab[6] mab humanized Notch 1 cancer
Burosumab[18] Crysvita mab human FGF 23 Y X-linked hypophosphatemia
Cabiralizumab[41] mab humanized CSF1R metastatic pancreatic cancer
Camidanlumab tesirine[26] mab human CD25 (α chain of IL-2 receptor) B-cell Hodgkin's lymphoma, non-Hodgkin lymphoma, acute lymphoblastic leukemia, acute myeloid leukemia
Camrelizumab[22] mab humanized PD-1 hepatocellular carcinoma
Canakinumab[43] Ilaris mab human IL-1 Y cryopyrin-associated periodic syndrome, Yao's Syndrome, Adult Onset Still's Disease
Cantuzumab mertansine[42] mab humanized CanAg (a glycoform of MUC1) colorectal cancer etc.
Cantuzumab ravtansine[42] mab humanized CanAg (a glycoform of MUC1) cancers
Caplacizumab[44] Cablivi sdAb humanized VWF Y thrombotic thrombocytopenic purpura, thrombosis
Casirivimab[29] mab human spike protein receptor binding domain (RBD) of SARS-CoV-2 Yes when used with imdevimab[45][46] COVID-19
Capromab[32] Prostascint mab mouse Glutamate carboxypeptidase II Y prostate cancer (detection)
Carlumab[16] mab human MCP-1 oncology/immune indications
Carotuximab[41] mab chimeric endoglin angiosarcoma
Catumaxomab[31] Removab 3funct rat/mouse hybrid EpCAM, CD3 Y ovarian cancer, malignant ascites, gastric cancer
cBR96-doxorubicin immunoconjugate mab humanized Lewis-Y antigen cancer
Cedelizumab[47] mab humanized CD4 prevention of organ transplant rejections, treatment of autoimmune diseases
Cemiplimab[32] Libtayo mab human PD-1 Y cutaneous squamous cell carcinoma
Cergutuzumab amunaleukin[12] mab humanized IL-2 cancer
Certolizumab pegol[43] Cimzia Fab' humanized TNF-α Y Crohn's disease, rheumatoid arthritis, axial spondyloarthritis, psoriasis arthritis
Cetrelimab[5] mab human PD-1 cancer
Cetuximab[32] Erbitux mab chimeric Epidermal growth factor receptor (EGFR) Y metastatic colorectal cancer and head and neck cancer
Cibisatamab[5] mab humanized CEACAM5 cancer
Cilgavimab[29] mab human spike protein receptor binding domain (RBD) of SARS-CoV-2 Emergency Use Authorization (EUA) when used with tixagevimab[48] COVID-19
Cirmtuzumab[32] humanized ROR1 chronic lymphocytic leukemia
Citatuzumab bogatox[49] Fab humanized EpCAM ovarian cancer and other solid tumors
Cixutumumab[32] mab human IGF-1 receptor (CD221) solid tumors
Clazakizumab[50] mab humanized IL-6 rheumatoid arthritis
Clenoliximab[32] mab chimeric CD4 rheumatoid arthritis
Clivatuzumab tetraxetan[32] hPAM4-Cide mab humanized MUC1 pancreatic cancer
Codrituzumab[4] mab humanized glypican 3 cancer
Cofetuzumab pelidotin[26] mab humanized PTK7 cancer
Coltuximab ravtansine[4] mab chimeric CD19 cancer
Conatumumab[49] mab human TRAIL-R2 cancer
Concizumab[51] Alhemo mab humanized tissue factor pathway inhibitor (TFPI) Y bleeding with hemophilia
Cosfroviximab[28] ZMapp mab chimeric ebolavirus glycoprotein Ebola virus
Cosibelimab[27] Unloxcyt[52] mab human Programmed death ligand-1 (PD-L1) Y cutaneous squamous cell carcinoma
Crenezumab[32] mab humanized β-amyloid (1-40 and 1-42) Alzheimer's disease
Crizanlizumab[22] Adakveo mab humanized selectin P Y sickle-cell disease
Crotedumab[41] mab human glucagon receptor (GCGR) diabetes
Crovalimab[53] Piasky mab humanized C5 Y paroxysmal nocturnal hemoglobinuria
CR6261 mab human Hemagglutinin (influenza) infectious disease/influenza A
Cusatuzumab[5] mab humanized CD70 cancer
Dacetuzumab[13] mab humanized CD40 hematologic cancers
Daclizumab[54] Zenapax mab humanized CD25 (α chain of IL-2 receptor) Y prevention of organ transplant rejections, multiple sclerosis
Dalotuzumab mab humanized IGF-1 receptor (CD221) cancer etc.
Dapirolizumab pegol[55] mab humanized CD154 (CD40L)
Daratumumab[56] Darzalex mab human CD38 Y[57] multiple myeloma
Dectrekumab[25] mab human IL-13
Demcizumab mab humanized DLL4 cancer
Denintuzumab mafodotin[6] mab humanized CD19 cancer
Denosumab[58] Prolia mab human RANKL Y osteoporosis, bone metastases etc.
Depatuxizumab mafodotin[22] mab chimeric/
humanized		 EGFR glioblastoma
Derlotuximab biotin mab chimeric histone complex recurrent glioblastoma multiforme
Detumomab mab mouse B-lymphoma cell lymphoma
Dezamizumab[22] mab humanized serum amyloid P component
Dinutuximab Unituxin mab chimeric GD2 ganglioside Y neuroblastoma
Dinutuximab beta Qarziba mab chimeric GD2 ganglioside Y neuroblastoma
Diridavumab mab human Hemagglutinin (influenza) influenza A
Divozilimab[29] Ivlizi mab humanized CD20 Y (Russia)[59] multiple sclerosis
Domagrozumab[41] mab humanized GDF-8 Duchenne muscular dystrophy
Donanemab[35] Kisunla[60] mab humanized Amyloid beta Y[60] Alzheimer's disease
Dorlimomab aritox[61] F(ab')2 mouse
Dostarlimab[62] Jemperli mab humanized PCDP1 Y endometrial cancer
Drozitumab mab human DR5 cancer etc.
DS-8201 humanized HER2 gastric or gastroesophageal junction adenocarcinoma
Duligotuzumab[15] mab humanized ERBB3 (HER3) testicular cancer
Dupilumab[40] Dupixent mab human IL-4Rα Y atopic dermatitis, asthma, nasal polyps
Durvalumab[25] Imfinzi mab human PD-L1 Y cancer
Dusigitumab mab human IGF-2 B-cell malignancies
Duvortuxizumab[28] scFv chimeric/
humanized		 CD19, CD3E cancer
Ecromeximab[21] mab chimeric GD3 ganglioside malignant melanoma
Eculizumab[21] Soliris mab humanized C5 Y paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome
Edobacomab mab mouse endotoxin sepsis caused by Gram-negative bacteria
Edrecolomab Panorex mab mouse EpCAM colorectal carcinoma
Efalizumab[7] Raptiva mab humanized LFA-1 (CD11a) psoriasis (blocks T-cell migration)
Efungumab[1] Mycograb scFv human Hsp90 invasive Candida infection
Eldelumab[4] mab human CXCL10 (IP-10) Crohn's disease, ulcerative colitis
Elezanumab[22] mab human repulsive guidance molecule A (RGMA) spinal cord injury and multiple sclerosis
Elgemtumab[25] mab human ERBB3 (HER3) cancer
Elotuzumab Empliciti mab humanized SLAMF7 Y multiple myeloma
Elsilimomab mab mouse IL-6
Emactuzumab[6] mab humanized CSF1R cancer
Emapalumab[22] Gamifant mab human IFN-γ Y hemophagocytic lymphohistiocytosis
Emibetuzumab mab humanized HGFR cancer
Emicizumab[12] Hemlibra BsAb humanized activated F9, F10 Y haemophilia A
Enapotamab vedotin[5] mab human AXL cancer
Enavatuzumab mab humanized TWEAK receptor cancer etc.
Enfortumab vedotin[4] Padcev mab human nectin-4 Y[63] urothelial cancer
Enlimomab pegol[64] mab mouse ICAM-1 (CD54)
Enoblituzumab[22] mab humanized CD276 cancer
Enokizumab mab humanized IL-9 asthma
Enoticumab[15] mab human DLL4
Ensituximab mab chimeric MUC5AC cancer
Epcoritamab Epkinly[27][65] BiTE humanized CD3, CD20 Y diffuse large B-cell lymphoma
Epitumomab cituxetan[66] mab mouse episialin
Epratuzumab mab humanized CD22 cancer, systemic lupus erythematosus (SLE)
Eptinezumab[22] Vyepti mab humanized calcitonin gene-related peptide Y[67] migraine
Erenumab[22] Aimovig mab human calcitonin gene-related peptide receptor (CGRP) Y migraine
Erlizumab[68] F(ab')2 humanized ITGB2 (CD18) heart attack, stroke, traumatic shock
Ertumaxomab[31] Rexomun 3funct rat/mouse hybrid HER2/neu, CD3 Y breast cancer etc.
Etaracizumab Abegrin mab humanized integrin αvβ3 Y melanoma, prostate cancer, ovarian cancer etc.
Etesevimab[29] mab human spike protein receptor binding domain (RBD) of SARS-CoV-2 Emergency Use Authorization (EUA) when used with bamlanivimab[30] COVID-19
Etigilimab[5] mab humanized TIGIT
Etrolizumab[16] mab humanized integrin β7 inflammatory bowel disease
Evinacumab Evkeeza mab human angiopoietin 3 Y dyslipidemia
Evolocumab[40] Repatha mab human PCSK9 Y hypercholesterolemia
Exbivirumab[69] mab human hepatitis B surface antigen hepatitis B
Fanolesomab[17] NeutroSpec mab mouse CD15 appendicitis (diagnosis)
Faralimomab mab mouse IFN receptor
Faricimab[5] Vabysmo mab humanized VEGF-A and Ang-2 Y angiogenesis, ocular vascular diseases
Farletuzumab mab humanized folate receptor 1 ovarian cancer
Fasinumab mab human nerve growth factor (NGF) acute sciatic pain
FBTA05[70][71] Lymphomun 3funct rat/mouse hybrid CD20 chronic lymphocytic leukaemia
Felvizumab mab humanized respiratory syncytial virus respiratory syncytial virus infection
Fezakinumab[72][73] mab human IL-22 rheumatoid arthritis, psoriasis
Fibatuzumab[74] mab humanized ephrin receptor A3
Ficlatuzumab mab humanized Hepatocyte growth factor (HGF) cancer etc.
Figitumumab mab human IGF-1 receptor (CD221) adrenocortical carcinoma, non-small cell lung carcinoma etc.
Firivumab[6] mab human Hemagglutinin (influenza)
Flanvotumab[44] mab human TYRP1 (glycoprotein 75) melanoma
Fletikumab mab human IL-20 rheumatoid arthritis
Flotetuzumab[5] di-scFv humanized IL-3 receptor hematological malignancies
Fontolizumab[21] HuZAF mab humanized IFN-γ Crohn's disease etc.
Foralumab[75] mab human CD3E
Foravirumab[49] mab human rabies virus glycoprotein rabies (prophylaxis)
Fremanezumab[22] Ajovy mab humanized calcitonin gene-related peptide alpha and beta Y migraine
Fresolimumab[56] mab human TGF-β idiopathic pulmonary fibrosis, focal segmental glomerulosclerosis, cancer
Frovocimab[62] mab humanized PCSK9 hypercholesterolemia
Frunevetmab[76] Solensia[77] mab veterinary nerve growth factor (NGF)[77] Y pain associated with osteoarthritis in cats[77]
Fulranumab mab human nerve growth factor (NGF) pain
Futuximab[15] mab chimeric Epidermal growth factor receptor (EGFR) cancer
Galcanezumab[41] Emgality mab humanized calcitonin Y migraine
Galiximab mab chimeric CD80 B-cell lymphoma
Gancotamab scFv human HER2/neu cancer
Ganitumab mab human IGF-1 receptor (CD221) cancer
Gantenerumab[43] mab human β-amyloid (1-40 and 1-42) Alzheimer's disease
Garadacimab[35] mab human Coagulation factor XIIa hereditary angioedema
Gatipotuzumab[28] mab humanized MUC1 cancer
Gavilimomab[68] mab mouse CD147 (basigin) graft versus host disease
Gedivumab[28] mab human Hemagglutinin (influenza)
Gemtuzumab ozogamicin[22] Mylotarg mab humanized CD33 Y acute myelogenous leukemia
Gevokizumab mab humanized IL-1β diabetes etc.
Gilvetmab[28] mab veterinary PCDC1
Gimsilumab[26] mab human CSF2 rheumatoid arthritis
Girentuximab[56] Rencarex mab chimeric carbonic anhydrase 9 (CA-IX) clear cell renal cell carcinoma[78]
Glembatumumab vedotin[38][79] mab human GPNMB melanoma, breast cancer
Glofitamab[27] Columvi[80] BsAb humanized CD20, CD3 Y[80] diffuse large B-cell lymphoma[80]
Golimumab[69] Simponi mab human TNF-α Y rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis
Gomiliximab mab chimeric CD23 (IgE receptor) allergic asthma
Gosuranemab mab humanized tau protein progressive supranuclear palsy
Guselkumab Tremfya mab human IL-23 Y psoriasis
Ianalumab[26] mab human BAFF-R autoimmune hepatitis
Ibalizumab[43] Trogarzo mab humanized CD4 Y HIV infection
Sintilimab human PD-1 squamous cell non-small cell lung cancer
Ibritumomab tiuxetan Zevalin mab mouse CD20 Y non-Hodgkin's lymphoma
Icrucumab mab human VEGFR-1 cancer etc.
Idarucizumab[4] Praxbind mab humanized dabigatran Y reversal of anticoagulant effects of dabigatran
Ifabotuzumab[22] mab humanized EPHA3 glioblastoma multiforme[81]
Igovomab Indimacis-125 F(ab')2 mouse CA-125 ovarian cancer (diagnosis)
Iladatuzumab vedotin[26] mab humanized CD79B cancer
Imalumab[6] mab human macrophage migration inhibitory factor (MIF) cancer
Imaprelimab[5] mab humanized melanoma cell adhesion molecule (MCAM)
Imciromab Myoscint mab mouse cardiac myosin Y cardiac imaging
Imdevimab[29] mab human spike protein receptor binding domain (RBD) of SARS-CoV-2 Yes when used with casirivimab[45][46] COVID-19
Imgatuzumab[15] mab humanized Epidermal growth factor receptor (EGFR) cancer
Inclacumab[44] mab human selectin P cardiovascular disease
Indatuximab ravtansine[42] mab chimeric SDC1 cancer
Indusatumab vedotin[25] mab human GUCY2C cancer
Inebilizumab[12] Uplizna mab humanized CD19 Y[82] cancer, systemic sclerosis, multiple sclerosis
Infliximab Remicade mab chimeric TNF-α Y rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis, Crohn's disease, ulcerative colitis
Intetumumab[83][84] mab human CD51 solid tumors (prostate cancer, melanoma)
Inolimomab mab mouse CD25 (α chain of IL-2 receptor) graft versus host disease
Inotuzumab ozogamicin[39] Besponsa mab humanized CD22 Y Acute lymphoblastic leukemia (ALL)
Ipilimumab[58] Yervoy mab human CD152 Y melanoma
Iomab-B mouse CD45 ablation of bone marrow
Iratumumab[58] mab human CD30 (TNFRSF8) Hodgkin's lymphoma
Isatuximab Sarclisa mab chimeric CD38 Y multiple myeloma
Iscalimab[5] mab human CD40
Istiratumab[26] mab human IGF-1 receptor (CD221) advanced solid tumors
Itolizumab[75] Alzumab mab humanized CD6 Y psoriasis
Ixekizumab Taltz mab humanized IL-17A Y autoimmune diseases
KappaMAB mab mouse Kappa Myeloma Antigen (KMA) multiple myeloma
Keliximab mab chimeric CD4 chronic asthma
Labetuzumab[7] CEA-Cide mab humanized Carcinoembryonic antigen (CEA) colorectal cancer
Lacnotuzumab[28] mab humanized CSF1, macrophage colony stimulating factor (MCSF) cancer
Ladiratuzumab vedotin[26] mab humanized LIV-1 cancer
Lampalizumab[15] Fab humanized Complement factor D (CFD) geographic atrophy secondary to age-related macular degeneration
Lanadelumab[41] Takhzyro mab human kallikrein Y angioedema
Landogrozumab[12] mab humanized GDF-8 muscle wasting disorders
Laprituximab emtansine[41] mab chimeric epidermal growth factor receptor (EGFR)
Larcaviximab[28] mab chimeric ebolavirus glycoprotein Ebola virus
Lebrikizumab mab humanized IL-13 asthma
Lecanemab[85] Leqembi mab humanized β-amyloid Y[86] Alzheimer's disease
Lemalesomab[68] mab mouse NCA-90 (granulocyte antigen) diagnostic agent
Lendalizumab[41] mab humanized C5
Lenvervimab[5] mab humanized hepatitis B surfage antigen hepatitis B
Lenzilumab[6] mab human CSF2 chronic myelomonocytic leukemia and juvenile myelomonocytic leukemia
Lerdelimumab[17] mab human TGF-β2 reduction of scarring after glaucoma surgery
Leronlimab[5] mab humanized CCR5 breast cancer, HIV
Lesofavumab[28] mab human Hemagglutinin (influenza)
Letolizumab[28] scFv humanized tumor necrosis factor related activation protein (TRAP) inflammatory diseases
Lexatumumab[1] mab human TRAIL-R2 cancer
Libivirumab[69] mab human hepatitis B surface antigen hepatitis B
Lifastuzumab vedotin mab humanized phosphate-sodium co-transporter cancer
Ligelizumab[15] mab humanized IGHE severe asthma, chronic spontaneous urticaria
Loncastuximab tesirine[87][74] Zynlonta mab chimeric CD19 Y relapsed or refractory large B-cell lymphoma
Losatuxizumab vedotin[28] mab chimeric/
humanized		 epidermal growth receptor factor (EGRF), ERBB1 HER1 cancer
Lilotomab satetraxetan[25] mab mouse CD37 cancer
Lintuzumab mab humanized CD33 cancer
Lirilumab[15] mab human KIR2D solid and hematological cancers
Lodelcizumab[40] mab humanized PCSK9 hypercholesterolemia
Lokivetmab[25] Cytopoint[88] mab veterinary Canis lupus familiaris IL31 Y clinical signs of atopic dermatitis in dogs[88]
Lorvotuzumab mertansine mab humanized CD56 cancer
Lucatumumab[13] mab human CD40 multiple myeloma, non-Hodgkin's lymphoma, Hodgkin's lymphoma
Lulizumab pegol[6] mab humanized CD28 autoimmune diseases
Lumiliximab[9] mab chimeric CD23 (IgE receptor) chronic lymphocytic leukemia
Lumretuzumab[6] mab humanized ERBB3 (HER3) cancer
Lupartumab[22] mab human
Lupartumab amadotin[22] mab human LYPD3
Lutikizumab[22] mab humanized IL-1α
Maftivimab mab human part of Atoltivimab/maftivimab/odesivimab for treatment of Zaire ebolavirus (Ebola virus)
Mapatumumab[31] mab human TRAIL-R1 cancer
Margetuximab Margenza[89] mab humanized HER2 Y breast cancer
Marstacimab Hympavzi[90][91] mab human tissue factor pathway inhibitor (TFPI) Y bleeding with hemophilia
Maslimomab mouse T-cell receptor
Mavrilimumab[38] mab human GMCSF receptor α-chain rheumatoid arthritis
Matuzumab[24] mab humanized Epidermal growth factor receptor (EGFR) colorectal, lung and stomach cancer
Mepolizumab[47] Bosatria mab humanized IL-5 Y asthma and white blood cell diseases
Metelimumab[24] mab human TGF-β1 systemic scleroderma
Milatuzumab[13] mab humanized CD74 multiple myeloma and other hematological malignancies
Minretumomab mab mouse TAG-72 tumor detection (and therapy?)
Mirikizumab[87] Omvoh mab humanized IL-23 Y ulcerative colitis
Mirvetuximab soravtansine[12] Elahere mab chimeric folate receptor alpha Y[92] ovarian cancer
Mitumomab mab mouse GD3 ganglioside small cell lung carcinoma
Modotuximab mab chimeric EGFR extracellular domain III cancer
Mogamulizumab[16] Poteligeo mab humanized CCR4 Y adult T-cell leukemia/lymphoma
Monalizumab[12] mab humanized NKG2A rheumatoid arthritis, gynecologic malignancies, and other cancers
Morolimumab[93] mab human Rhesus factor
Mosunetuzumab[87] Lunsumio BiTE humanized CD3E, MS4A1, CD20 Y[94] follicular lymphoma
Motavizumab[1] Numax mab humanized respiratory syncytial virus respiratory syncytial virus (prevention)
Moxetumomab pasudotox Lumoxiti mab mouse CD22 Y hairy cell leukemia
Muromonab-CD3[95][96] Orthoclone OKT3 mab mouse CD3 prevention of organ transplant rejections
Nacolomab tafenatox Fab mouse C242 antigen colorectal cancer
Namilumab[16] mab human CSF2
Naptumomab estafenatox[97] Fab mouse 5T4 non-small cell lung carcinoma, renal cell carcinoma
Naratuximab emtansine[41] mab chimeric CD37
Narnatumab mab human MST1R (aka RON) cancer
Natalizumab[93] Tysabri mab humanized integrin α4 Y multiple sclerosis, Crohn's disease
Navicixizumab[41] mab chimeric/
humanized		 DLL4 and VEGFA cancer
Navivumab[12] mab human Hemagglutinin (influenza)
Naxitamab Danyelza humanized c-Met Y high-risk neuroblastoma and refractory osteomedullary disease
Nebacumab mab human endotoxin sepsis
Necitumumab[98] Portrazza mab human Epidermal growth factor receptor (EGFR) Y non-small cell lung carcinoma
Nemolizumab[25] mab humanized IL-31 receptor A eczema[99]
NEOD001 humanized amyloid primary systemic amyloidosis
Nerelimomab mab mouse TNF-α
Nesvacumab mab human angiopoietin 2 cancer
Netakimab[5] Efleira mab humanized IL-17A Y (Russia)[100] plaque psoriasis, psoriatic arthritis, ankylosing spondylitis
Nimotuzumab[58][101] BioMab-EGFR, Theracim, Theraloc mab humanized epidermal growth factor receptor (EGFR) Y squamous cell carcinoma, head and neck cancer, nasopharyngeal cancer, glioma
Nirsevimab mab human RSV fusion glycoprotein respiratory syncytial virus
Nivolumab[6] Opdivo mab human PD-1 Y cancer
Nofetumomab merpentan Verluma Fab mouse cancer (diagnosis)
Obiltoxaximab Anthim mab chimeric Bacillus anthracis anthrax Y Bacillus anthracis spores
Obinutuzumab Gazyva mab humanized CD20 Y chronic lymphatic leukemia
Ocaratuzumab mab humanized CD20 cancer
Ocrelizumab[102] Ocrevus mab humanized CD20 Y multiple sclerosis
Odesivimab mab human part of Atoltivimab/maftivimab/odesivimab for treatment of Zaire ebolavirus (Ebola virus)
Odulimomab mab mouse LFA-1 (CD11a) prevention of organ transplant rejections, immunological diseases
Ofatumumab[31] Arzerra, Kesimpta[103] mab human CD20 Y chronic lymphocytic leukemia, multiple sclerosis[103]
Olaratumab Lartruvo mab human PDGFRA Y cancer
Oleclumab[28] mab human 5'-nucleotidase pancreatic and colorectal cancer
Olendalizumab[28] mab humanized complement C5a systemic lupus erythematosus, lupus nephritis, acute graft-versus-hose disease
Olokizumab[75] mab humanized IL-6 rheumatoid arthritis
Omalizumab[68] Xolair mab humanized IgE Fc region Y allergic asthma, chronic spontaneous urticaria
Omburtamab[62] mab mouse CD276 cancer
OMS721 human MASP-2 atypical hemolytic uremic syndrome
Onartuzumab Fab humanized human scatter factor receptor kinase cancer
Ontuxizumab mab chimeric/
humanized		 TEM1 cancer
Onvatilimab[5] mab human VISTA (protein) (VSIR)
Opicinumab mab human LINGO-1 multiple sclerosis
Oportuzumab monatox[98] Vicinium scFv humanized EpCAM bladder cancer
Oregovomab[17] OvaRex mab mouse CA-125 ovarian cancer
Orticumab[15] mab human oxLDL
Otelixizumab[13] mab chimeric/
humanized		 CD3 diabetes mellitus type 1
Otilimab mab human GMCSF osteoarthritis, rheumatoid arthritis
Otlertuzumab mab humanized CD37 cancer
Oxelumab[42] mab human OX-40 asthma
Ozanezumab mab humanized NOGO-A ALS and multiple sclerosis
Ozoralizumab[42] mab humanized TNF-α inflammation
Pagibaximab[31] mab chimeric lipoteichoic acid sepsis (Staphylococcus)
Palivizumab Synagis, Abbosynagis mab humanized F protein of respiratory syncytial virus Y respiratory syncytial virus (prevention)
Pamrevlumab[12] mab human connective tissue growth factor (CTGF) idiopathic pulmonary fibrosis (IPF), pancreatic cancer
Panitumumab[69] Vectibix mab human epidermal growth factor receptor (EGFR) Y colorectal cancer
Pankomab mab humanized tumor specific glycosylation of MUC1 ovarian cancer
Panobacumab[98] mab human Pseudomonas aeruginosa Pseudomonas aeruginosa infection
Parsatuzumab[15] mab humanized EGFL7 cancer
Pascolizumab[21] mab humanized IL-4 asthma
Pasotuxizumab[6] mab chimeric/
humanized		 folate hydrolase cancer
Pateclizumab[42] mab humanized lymphotoxin alpha (LTA) TNF
Patritumab[44] mab human ERBB3 (HER3) cancer
PDR001 humanized PD-1 melanoma
Pembrolizumab[55] Keytruda mab humanized PD-1 Y[104] melanoma and other cancers
Pemivibart[105] Pemgarda mab human spike protein receptor binding domain (RBD) of SARS-CoV-2 Emergency Use Authorization (EUA)[106] COVID-19
Pemtumomab Theragyn mouse MUC1 cancer
Perakizumab[15] mab humanized IL-17A arthritis
Pertuzumab Perjeta mab humanized HER2/neu Y cancer
Pexelizumab[17] scFv humanized C5 reduction of side effects of cardiac surgery
Pidilizumab[40] mab humanized PD-1 cancer and infectious diseases
Pinatuzumab vedotin[40] mab humanized CD22 cancer
Pintumomab mab mouse adenocarcinoma antigen adenocarcinoma (imaging)
Placulumab[15] mab human TNF pain and inflammatory diseases
Pozelimab[35] Veopoz mab human C5 Y CHAPLE disease
Prezalumab[41] mab human TNF
Plozalizumab[12] mab humanized CCR2 diabetic nephropathy and arteriovenous graft patency
Pogalizumab[41] mab humanized tumor necrosis factor receptor (TNFR) superfamily member 4
Polatuzumab vedotin[51][4] Polivy mab humanized CD79B Y diffuse large B-cell lymphoma
Ponezumab mab humanized β-amyloid Alzheimer's disease
Porgaviximab[28] mab chimeric Zaire ebolavirus glycoprotein Ebola virus disease
Prasinezumab[26] mab humanized Alpha-synuclein Parkinson's disease
Prezalizumab[41] mab humanized inducible T-cell co-stimulatory ligand (ICOSL)
Priliximab mab chimeric CD4 Crohn's disease, multiple sclerosis
Pritoxaximab[40] mab chimeric E. coli shiga toxin type-1
Pritumumab mab human vimentin brain cancer
PRO 140 humanized CCR5 HIV infection
Quilizumab[44] mab humanized IGHE asthma
Racotumomab[98] Vaxira mab mouse NGNA ganglioside Y non-small cell lung cancer
Radretumab[16] mab human fibronectin extra domain-B cancer
Rafivirumab[49] mab human rabies virus glycoprotein rabies (prophylaxis)
Ralpancizumab mab humanized PCSK9 dyslipidemia
Ramucirumab Cyramza mab human VEGFR2 Y solid tumors
Ranevetmab mab veterinary NGF osteoarthritis in dogs
Ranibizumab[9] Lucentis Fab humanized VEGF-A Y macular degeneration (wet form)
Raxibacumab[39] mab human anthrax toxin, protective antigen Y anthrax (prophylaxis and treatment)
Ravagalimab[5] mab humanized CD40 Crohn's disease
Ravulizumab[26] Ultomiris mab humanized C5 Y paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome
Refanezumab mab humanized myelin-associated glycoprotein recovery of motor function after stroke
Regavirumab mab human cytomegalovirus glycoprotein B cytomegalovirus infection
Regdanvimab[29] Regkirona[107] mab human spike protein receptor binding domain (RBD) of SARS-CoV-2 Y[107] COVID-19
Relatlimab mab human LAG3 melanoma
Remtolumab[22] mab human IL-17A, TNF
Reslizumab[7] Cinqair mab humanized IL-5 Y inflammations of the airways, skin and gastrointestinal tract
Retifanlimab[27] Zynyz[108] mab humanized PD-1 Y Merkel cell carcinoma
Rilotumumab mab human hepatocyte growth factor (HGF) solid tumors
Rinucumab mab human PDGFRB neovascular age-related macular degeneration
Risankizumab[12] Skyrizi mab humanized IL-23A Y Crohn's disease, psoriasis, psoriatic arthritis, and asthma
Rituximab MabThera, Rituxan mab chimeric CD20 Y[109] lymphomas, leukemias, some autoimmune disorders
Rivabazumab pegol[12] mab humanized Pseudomonas aeruginosa type III secretion system
Robatumumab mab human IGF-1 receptor (CD221) cancer
Rmab RabiShield human rabies virus G glycoprotein Y post-exposure prophylaxis of rabies
Roledumab[75] mab human RHD (gene) (RHD) Rh disease
Romilkimab[5] mab chimeric/
humanized		 IL-13
Romosozumab[44] Evenity mab humanized sclerostin Y osteoporosis
Rontalizumab[56] mab humanized IFN-α systemic lupus erythematosus
Rosmantuzumab[22] mab humanized root plate-specific spondin 3 cancer
Rovalpituzumab tesirine[12] mab humanized DLL3 small cell lung cancer
Rovelizumab[47] LeukArrest mab humanized CD11, CD18 Y haemorrhagic shock etc.
Rozanolixizumab[22] Rystiggo mab chimeric/
humanized		 FCGRT Y[110] myasthenia gravis
Ruplizumab[14] Antova mab humanized CD154 (CD40L) Y rheumatic diseases
SA237 humanized IL-6 receptor neuromyelitis optica and neuromyelitis optica spectrum disorders
Sacituzumab govitecan[22] Trodelvy mab humanized TROP-2 Y[111] triple-negative breast cancer
Samalizumab[42] mab humanized CD200 cancer
Samrotamab vedotin[5] mab chimeric/
humanized		 LRRC15 cancer
Sarilumab[44] Kevzara mab human IL-6 Y rheumatoid arthritis, ankylosing spondylitis
Satralizumab[76] Enspryng mab humanized IL-6 receptor Y neuromyelitis optica
Satumomab pendetide mab mouse TAG-72 cancer (diagnosis)
Secukinumab Cosentyx mab human IL-17A Y uveitis, rheumatoid arthritis psoriasis
Selicrelumab[28] mab human CD40
Seribantumab[40] mab human ERBB3 (HER3) cancer
Setoxaximab[40] mab chimeric E. coli shiga toxin type-2
Setrusumab[26] mab human sclerostin (SOST)
Sevirumab human cytomegalovirus cytomegalovirus infection
Sibrotuzumab mab humanized FAP (gene) (FAP) cancer
SGN-CD19A mab humanized CD19 acute lymphoblastic leukemia and B-cell non-Hodgkin lymphoma
SHP647 human mucosal addressin cell adhesion molecule Crohn's disease
Sifalimumab[16] mab human IFN-α systemic lupus erythematosus (SLE), dermatomyositis, polymyositis
Siltuximab Sylvant mab chimeric IL-6 Y cancer
Simtuzumab[15] mab humanized LOXL2 fibrosis
Sipavibart[105] mab human spike protein receptor binding domain (RBD) of SARS-CoV-2 COVID-19
Siplizumab[21] mab humanized CD2 psoriasis, graft-versus-host disease (prevention)
Sirtratumab vedotin[26] mab human SLITRK6 cancer
Sirukumab mab human IL-6 rheumatoid arthritis
Sofituzumab vedotin mab humanized CA-125 ovarian cancer
Solanezumab[98][44] mab humanized β-amyloid Alzheimer's disease
Solitomab[44] BiTE mouse EpCAM gastrointestinal, lung, and other cancers
Sonepcizumab[112] humanized sphingosine-1-phosphate choroidal and retinal neovascularization
Sontuzumab[101] mab humanized episialin
Sotrovimab[29] Xevudy mab human spike protein receptor binding domain (RBD) of SARS-CoV-2 Y[113][114] COVID-19
Spartalizumab[26] mab humanized PD-1 melanoma
Spesolimab[53] Spevigo mab humanized Interleukin 36 receptor (IL1RL2/IL1RAP) Y generalized pustular psoriasis (GPP)
Stamulumab[102] mab human myostatin muscular dystrophy
Sugemalimab[85] mab human PD-1 non-small-cell lung cancer
Sulesomab LeukoScan Fab' mouse NCA-90 (granulocyte antigen) osteomyelitis (imaging)
Suptavumab[22] mab human RSVFR medically attended lower respiratory disease
Sutimlimab[5] Enjaymo mab chimeric/
humanized		 complement component 1s (C1s) Y cold agglutinin disease
Suvizumab[38] mab humanized HIV-1 viral infections
Suvratoxumab[28] mab human Staphylococcus aureus alpha toxin nosocomial pneumonia
Tabalumab[42] mab human B-cell activating factor (BAFF) B-cell cancers
Tacatuzumab tetraxetan AFP-Cide mab humanized alpha-fetoprotein cancer
Tadocizumab[101] Fab humanized integrin αIIbβ3 percutaneous coronary intervention
Tafasitamab[47] Monjuvi mab humanized
(from mouse)		 CD19 Y relapsed or refractory diffuse large B-cell lymphoma
Talacotuzumab[26] mab humanized CD123 leukemia etc.
Talizumab[37] mab humanized IgE allergic reaction
Talquetamab Talvey BsAb humanized GPRC5D, CD3 Y relapsed or refractory multiple myeloma
Tamtuvetmab[41] Tactress mab veterinary CD52
Tanezumab[49] mab humanized nerve growth factor (NGF) pain
Taplitumomab paptox[68] mab mouse CD19 cancer[citation needed]
Tarextumab mab human Notch receptor cancer
Tarlatamab[29] Imdelltra[115] BsAb human DLL3, CD3[115] Y[115] small cell lung cancer[115]
Tavolimab mab chimeric/
humanized		 CD134 cancer
Teclistamab Tecvayli[35] BsAb human B-cell maturation antigen (BCMA), CD3 Y[116][117] relapsed or refractory multiple myeloma
Tefibazumab[39] Aurexis mab humanized clumping factor A Staphylococcus aureus infection
Telimomab aritox Fab mouse
Telisotuzumab[22] mab humanized HGFR cancer
Telisotuzumab vedotin[22] mab humanized HGFR cancer
Tenatumomab[13] mab mouse tenascin C cancer
Teneliximab[21] mab chimeric CD40 autoimmune diseases and prevention of organ transplant rejection
Teplizumab[43] Tzield mab humanized CD3 Y diabetes mellitus type 1
Tepoditamab[5] mab human dendritic cell-associated lectin 2 cancer
Teprotumumab Tepezza mab human IGF-1 receptor (CD221) Y thyroid eye disease
Tesidolumab[25] mab human C5
Tetulomab mab humanized CD37 cancer[118]
Tezepelumab[12] Tezspire mab human thymic stromal lymphopoietin (TSLP) Y[119] asthma
TGN1412 humanized CD28 chronic lymphocytic leukemia, rheumatoid arthritis
Tibulizumab[26] mab humanized B-cell activating factor (BAFF) autoimmune disorders
Tildrakizumab Ilumya mab humanized IL-23 Y immunologically mediated inflammatory disorders
Tigatuzumab[13] mab humanized TRAIL-R2 cancer
Timigutuzumab[28] mab humanized HER2 cancer
Timolumab[41] mab human AOC3
tiragolumab[26] mab human
Tiragotumab[26] mab human TIGIT cancer
Tislelizumab[26] mab humanized PCDC1, CD279 non-small cell lung cancer
Tisotumab vedotin[12] Tivdak mab human coagulation factor III Y relapsed or refractory cervical cancer[120][121]
Tixagevimab[29] mab human spike protein receptor binding domain (RBD) of SARS-CoV-2 Emergency Use Authorization (EUA) when used with cilgavimab[48] COVID-19
TNX-650 humanized IL-13 Hodgkin's lymphoma
Tocilizumab[9] Actemra, RoActemra mab humanized IL-6 receptor Y[122] rheumatoid arthritis
Tomuzotuximab[28] mab humanized Epidermal growth factor receptor (EGFR), HER1 cancer
Toralizumab[21] mab humanized CD154 (CD40L) rheumatoid arthritis, lupus nephritis etc.
Tosatoxumab[4] mab human Staphylococcus aureus
Tositumomab Bexxar mouse CD20 Y follicular lymphoma
Tovetumab mab human PDGFRA cancer
Tralokinumab[123] Adtralza, Adbry[124] mab human IL-13 Y[124] atopic dermatitis
Trastuzumab Herceptin mab humanized HER2/neu Y breast cancer
Trastuzumab duocarmazine[22] Kadcyla mab humanized HER2/neu Y breast cancer
Trastuzumab emtansine Kadcyla mab humanized HER2/neu Y breast cancer
TRBS07[125] Ektomab 3funct GD2 ganglioside melanoma
Tregalizumab[16] mab humanized CD4
Tremelimumab[126] Imjudo mab human CTLA-4 Y[127] hepatocellular carcinoma
Trevogrumab mab human growth differentiation factor 8 muscle atrophy due to orthopedic disuse and sarcopenia
Tucotuzumab celmoleukin[58][101] mab humanized EpCAM cancer
Tuvirumab human hepatitis B virus chronic hepatitis B
Ublituximab[128] Briumvi mab chimeric CD20 Y multiple sclerosis, chronic lymphocytic leukemia
Ulocuplumab[55] mab human CXCR4 (CD184) hematologic malignancies
Urelumab[16] mab human 4-1BB (CD137) cancer etc.
Urtoxazumab[9] mab humanized Escherichia coli diarrhoea caused by E. coli
Ustekinumab[49] Stelara mab human IL-12, IL-23 Y multiple sclerosis, psoriasis, psoriatic arthritis
Utomilumab[22] mab human 4-1BB (CD137) diffuse large B-cell lymphoma
Vadastuximab talirine[12] mab chimeric CD33 Acute myeloid leukemia
Vanalimab[5] mab humanized CD40
Vandortuzumab vedotin[25] mab humanized STEAP1 cancer
Vantictumab mab human Frizzled receptor cancer
Vanucizumab[6] mab humanized angiopoietin 2 cancer
Vapaliximab[21] mab chimeric AOC3 (VAP-1)
Varisacumab[28] mab human VEGF-A angiogenesis
Varlilumab[6] mab human CD27 solid tumors and hematologic malignancies
Vatelizumab[42] mab humanized ITGA2 (CD49b)
Vedolizumab[98] Entyvio mab humanized integrin α4 β7 Y[129] Crohn's disease, ulcerative colitis
Veltuzumab[13] mab humanized CD20 non-Hodgkin's lymphoma
Vepalimomab mab mouse AOC3 (VAP-1) inflammation
Vesencumab[16] mab human NRP1 solid malignancies
Vilobelimab[85] Gohibic mab chimeric C5a receptor (C5a) Emergency Use Authorization (EUA)[130] COVID-19
Visilizumab[68] Nuvion mab humanized CD3 Crohn's disease, ulcerative colitis
Vobarilizumab[41] scFv humanized IL-6 receptor inflammatory autoimmune diseases
Volociximab[31] mab chimeric integrin α5β1 solid tumors
Vonlerolizumab[28] mab humanized CD134 cancer
Vopratelimab[5] mab humanized CD278, aka ICOS
Vorsetuzumab mafodotin mab humanized CD70 cancer
Votumumab HumaSPECT mab human tumor antigen CTAA16.88 colorectal tumors
Vunakizumab[22] mab humanized IL-17A
Xentuzumab[41] mab humanized IGF-1, IGF-2 ?
XMAB-5574 humanized CD19 diffuse large B-cell lymphoma
Zalutumumab[31] mab human Epidermal growth factor receptor (EGFR) squamous cell carcinoma of the head and neck
Zanidatamab[14] Ziihera[131] BsAb humanized HER2, HER2 Y biliary tract cancer[131]
Zanolimumab[39] mab human CD4 rheumatoid arthritis, psoriasis, T-cell lymphoma
Zatuximab[15] mab chimeric HER1 cancer
Zenocutuzumab[87] Bizengri[132] BsAb humanized HER2, ERBB3 (HER3) Y[132] cancer
Ziralimumab[68] mab human CD147 (basigin)
Zolbetuximab[26] Vyloy[133] mab chimeric Claudin 18 Isoform 2 Y gastric cancer
Zolimomab aritox mab mouse CD5 systemic lupus erythematosus, graft-versus-host disease

References

[edit]
  1. ^ a b c d e World Health Organization (2007). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 57". WHO Drug Information. 21 (1). hdl:10665/74004.
  2. ^ a b c World Health Organization (1998). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 80" (PDF). WHO Drug Information. 12 (4). Archived (PDF) from the original on 15 July 2020. Retrieved 23 January 2020.
  3. ^ "ReoPro Abciximab". DailyMed. 4 May 2020. Archived from the original on 6 September 2022. Retrieved 28 June 2022.
  4. ^ a b c d e f g h i j World Health Organization (2014). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 71". WHO Drug Information. 28 (1). hdl:10665/331151.
  5. ^ a b c d e f g h i j k l m n o p q r s t u v w World Health Organization (2018). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 80". WHO Drug Information. 32 (3). hdl:10665/330907.
  6. ^ a b c d e f g h i j k l m n o World Health Organization (2014). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 111" (PDF). WHO Drug Information. 28 (2). Archived (PDF) from the original on 15 August 2020. Retrieved 5 October 2020.
  7. ^ a b c d World Health Organization (2001). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 85" (PDF). WHO Drug Information. 15 (2). Archived (PDF) from the original on 15 July 2020. Retrieved 23 January 2020.
  8. ^ "Humira- adalimumab kit Humira- adalimumab injection, solution". DailyMed. Archived from the original on 21 June 2020. Retrieved 18 February 2020.
  9. ^ a b c d e World Health Organization (2004). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 90" (PDF). WHO Drug Information. 18 (1). Archived (PDF) from the original on 15 August 2020. Retrieved 23 January 2020.
  10. ^ a b World Health Organization (2014). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 72". WHO Drug Information. 28 (3). hdl:10665/331112.
  11. ^ "Aduhelm- aducanumab injection, solution". DailyMed. Archived from the original on 14 June 2021. Retrieved 14 June 2021.
  12. ^ a b c d e f g h i j k l m n o p q r s World Health Organization (2016). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 75". WHO Drug Information. 30 (1). hdl:10665/331046.
  13. ^ a b c d e f g h i World Health Organization (2007). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 98" (PDF). WHO Drug Information. 21 (4). Archived (PDF) from the original on 3 March 2016. Retrieved 5 October 2020.
  14. ^ a b c d World Health Organization (2000). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 83" (PDF). WHO Drug Information. 14 (2). Archived (PDF) from the original on 15 August 2020. Retrieved 23 January 2020.
  15. ^ a b c d e f g h i j k l m n World Health Organization (2012). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 107" (PDF). WHO Drug Information. 26 (2). Archived (PDF) from the original on 7 August 2020. Retrieved 23 January 2020.
  16. ^ a b c d e f g h i j k World Health Organization (2010). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 104" (PDF). WHO Drug Information. 24 (4). Archived (PDF) from the original on 15 July 2020. Retrieved 23 January 2020.
  17. ^ a b c d e World Health Organization (2002). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 86" (PDF). WHO Drug Information. 16 (1). Archived (PDF) from the original on 11 August 2020. Retrieved 23 January 2020.
  18. ^ a b c World Health Organization (2016). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 115" (PDF). WHO Drug Information. 30 (2). Archived (PDF) from the original on 5 February 2018. Retrieved 5 October 2020.
  19. ^ "Saphnelo- anifrolumab injection, solution". DailyMed. Archived from the original on 12 August 2021. Retrieved 11 August 2021.
  20. ^ "Wyeth.com | Complete Project Listing". Wyeth. 2008. Archived from the original on 12 June 2008. Retrieved 19 November 2008.
  21. ^ a b c d e f g h i World Health Organization (2002). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 87" (PDF). WHO Drug Information. 16 (2). Archived (PDF) from the original on 7 August 2020. Retrieved 23 January 2020.
  22. ^ a b c d e f g h i j k l m n o p q r s t u v w x y z World Health Organization (2017). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 77". WHO Drug Information. 31 (1). hdl:10665/330984.
  23. ^ World Health Organization (1995). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 74" (PDF). WHO Drug Information. 9 (4). Archived (PDF) from the original on 7 August 2020. Retrieved 24 January 2020.
  24. ^ a b c d World Health Organization (2003). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 88" (PDF). WHO Drug Information. 17 (1). Archived (PDF) from the original on 15 July 2020. Retrieved 23 January 2020.
  25. ^ a b c d e f g h i j k World Health Organization (2014). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 112" (PDF). WHO Drug Information. 28 (4). Archived (PDF) from the original on 28 August 2021. Retrieved 5 October 2020.
  26. ^ a b c d e f g h i j k l m n o p q r s t u World Health Organization (2017). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 117" (PDF). WHO Drug Information. 31 (2). Archived (PDF) from the original on 15 August 2020. Retrieved 5 October 2020.
  27. ^ a b c d e World Health Organization (2020). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 83". WHO Drug Information. 34 (1). hdl:10665/339768.
  28. ^ a b c d e f g h i j k l m n o p q r s t World Health Organization (2016). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 116" (PDF). WHO Drug Information. 30 (4). Archived (PDF) from the original on 7 August 2020. Retrieved 5 October 2020.
  29. ^ a b c d e f g h i j World Health Organization (2021). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 85". WHO Drug Information. 35 (1). hdl:10665/340684.
  30. ^ a b "Fact Sheet For Health Care Providers Emergency Use Authorization (EUA) Of Bamlanivimab and Etesevimab" (PDF). U.S. Food and Drug Administration (FDA). Archived from the original on 18 March 2021. Retrieved 18 March 2021.
  31. ^ a b c d e f g h World Health Organization (2008). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 93" (PDF). WHO Drug Information. 19 (2). Archived (PDF) from the original on 15 July 2020. Retrieved 23 January 2020.
  32. ^ a b c d e f g h i j k l m n o p q r World Health Organization (2019). International Nonproprietary Names (INN) for biological and biotechnological substances (PDF). World Health Organization (WHO). WHO/EMP/RHT/TSN/2019.1. Archived (PDF) from the original on 19 January 2022. Retrieved 22 January 2020.
  33. ^ World Health Organization (2021). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 126 – COVID-19 (special edition)". WHO Drug Information. 35 (4): 1130–1. Archived from the original on 13 February 2022. Retrieved 13 February 2022.
  34. ^ "Fact Sheet For Health Care Providers Emergency Use Authorization (EUA) Of Bebtelovimab" (PDF). U.S. Food and Drug Administration (FDA). Archived from the original on 11 February 2022. Retrieved 12 February 2022.
  35. ^ a b c d e World Health Organization (2019). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 82". WHO Drug Information. 33 (3). hdl:10665/330879.
  36. ^ a b c "Zoetis Announces U.S. FDA Approval of Librela (bedinvetmab injection) to Control Osteoarthritis (OA) Pain in Dogs" (Press release). Zoetis. 5 May 2023. Archived from the original on 6 May 2023. Retrieved 13 May 2023 – via Business Wire.
  37. ^ a b World Health Organization (2003). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 89" (PDF). WHO Drug Information. 17 (3).
  38. ^ a b c d World Health Organization (2009). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 102" (PDF). WHO Drug Information. 23 (4). Archived (PDF) from the original on 11 August 2020. Retrieved 23 January 2020.
  39. ^ a b c d e World Health Organization (2004). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 92" (PDF). WHO Drug Information. 18 (4). Archived (PDF) from the original on 15 July 2020. Retrieved 23 January 2020.
  40. ^ a b c d e f g h i World Health Organization (2012). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 108" (PDF). WHO Drug Information. 26 (4). Archived (PDF) from the original on 4 March 2016. Retrieved 5 October 2020.
  41. ^ a b c d e f g h i j k l m n o p q r World Health Organization (2015). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 114" (PDF). WHO Drug Information. 29 (4). Archived (PDF) from the original on 7 August 2020. Retrieved 5 October 2020.
  42. ^ a b c d e f g h i j k World Health Organization (2011). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 105" (PDF). WHO Drug Information. 25 (2). Archived (PDF) from the original on 11 August 2020. Retrieved 23 January 2020.
  43. ^ a b c d e World Health Organization (2007). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 97" (PDF). WHO Drug Information. 21 (2). Archived (PDF) from the original on 15 July 2020. Retrieved 23 January 2020.
  44. ^ a b c d e f g h i World Health Organization (2012). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 68". WHO Drug Information. 26 (3). hdl:10665/109813.
  45. ^ a b "Ronapreve EPAR". European Medicines Agency. 10 November 2021. Archived from the original on 13 November 2021. Retrieved 12 November 2021.
  46. ^ a b "Japan becomes first country to approve Ronapreve (casirivimab and imdevimab) for the treatment of mild to moderate COVID-19". Roche (Press release). 20 July 2021. Archived from the original on 24 July 2021. Retrieved 29 August 2021.
  47. ^ a b c d World Health Organization (1999). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 81" (PDF). WHO Drug Information. 13 (2). Archived (PDF) from the original on 15 July 2020. Retrieved 23 January 2020.
  48. ^ a b "Coronavirus (COVID-19) Update: FDA Authorizes New Long-Acting Monoclonal Antibodies for Pre-exposure Prevention of COVID-19 in Certain Individuals". U.S. Food and Drug Administration (FDA) (Press release). 8 December 2021. Archived from the original on 28 April 2022. Retrieved 9 December 2021. Public Domain This article incorporates text from this source, which is in the public domain.
  49. ^ a b c d e f World Health Organization (2008). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 99" (PDF). WHO Drug Information. 22 (2). Archived (PDF) from the original on 25 October 2021. Retrieved 5 October 2020.
  50. ^ "BMS Shells Out $85M Up Front for Alder's Mid-Stage Rheumatoid Arthritis Antibody". Genetic Engineering & Biotechnology News. 10 November 2009. Archived from the original on 13 November 2009. Retrieved 11 November 2009.
  51. ^ a b World Health Organization (2013). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 70". WHO Drug Information. 27 (3). hdl:10665/331167.
  52. ^ "FDA approves cosibelimab-ipdl". U.S. Food and Drug Administration (FDA). 13 December 2024. Retrieved 17 December 2024.
  53. ^ a b World Health Organization (2019). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 81". WHO Drug Information. 33 (1). hdl:10665/330896.
  54. ^ World Health Organization (1997). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 78" (PDF). WHO Drug Information. 11 (4). Archived (PDF) from the original on 7 August 2020. Retrieved 23 January 2020.
  55. ^ a b c World Health Organization (2013). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 110" (PDF). WHO Drug Information. 27 (4). Archived (PDF) from the original on 7 August 2020. Retrieved 5 October 2020.
  56. ^ a b c d World Health Organization (2009). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 101" (PDF). WHO Drug Information. 23 (2). Archived (PDF) from the original on 11 August 2020. Retrieved 23 January 2020.
  57. ^ "Darzalex- daratumumab injection, solution, concentrate Darzalex IV- daratumumab injection, solution, concentrate". DailyMed. Archived from the original on 19 December 2021. Retrieved 18 December 2021.
  58. ^ a b c d e World Health Organization (2005). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 94" (PDF). WHO Drug Information. 19 (4). Archived (PDF) from the original on 15 July 2020. Retrieved 23 January 2020.
  59. ^ "Ivlizi (divozilimab) Concentrate for Solution for Infusion. Full Prescribing Information". Russian State Register of Medicines (in Russian). JSC Biocad. Retrieved 28 January 2024.
  60. ^ a b "FDA approves treatment for adults with Alzheimer's disease". U.S. Food and Drug Administration (FDA) (Press release). 2 July 2024. Archived from the original on 2 July 2024. Retrieved 2 July 2024.
  61. ^ World Health Organization (1991). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 66" (PDF). WHO Drug Information. 5 (4). Archived (PDF) from the original on 15 August 2020. Retrieved 23 January 2020.
  62. ^ a b c World Health Organization (2018). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 119" (PDF). WHO Drug Information. 32 (2). Archived (PDF) from the original on 11 August 2020. Retrieved 5 October 2020.
  63. ^ "Padcev ejfv- enfortumab vedotin injection, powder, lyophilized, for solution". DailyMed. Archived from the original on 11 December 2021. Retrieved 18 December 2021.
  64. ^ World Health Organization (1997). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 77" (PDF). WHO Drug Information. 11 (2). Archived (PDF) from the original on 11 August 2020. Retrieved 23 January 2020.
  65. ^ World Health Organization (2022). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 88". WHO Drug Information. 36 (3). hdl:10665/363551.
  66. ^ World Health Organization (2004). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 51" (PDF). WHO Drug Information. 18 (1). Archived (PDF) from the original on 15 July 2020. Retrieved 23 January 2020.
  67. ^ "Vyepti- eptinezumab-jjmr injection". DailyMed. Archived from the original on 28 September 2021. Retrieved 27 September 2021.
  68. ^ a b c d e f g World Health Organization (2000). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 84" (PDF). WHO Drug Information. 14 (4). Archived (PDF) from the original on 15 July 2020. Retrieved 23 January 2020.
  69. ^ a b c d World Health Organization (2004). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 91" (PDF). WHO Drug Information. 18 (2). Archived (PDF) from the original on 15 July 2020. Retrieved 23 January 2020.
  70. ^ Buhmann, R; Simoes, B; Stanglmaier, M; Yang, T; Faltin, M; Bund, D; Lindhofer, H; Kolb, HJ; et al. (2008). "Immunotherapy of recurrent B–cell malignancies after allo SCT with Bi20 (FBTA05), a trifunctional anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion". Bone Marrow Transplantation. 43 (5): 383–397. doi:10.1038/bmt.2008.323. PMID 18850012.
  71. ^ Boehrer, S; Schroeder, Petra; Mueller, Tina; Atz, Judith; Chow, Kai Uwe; et al. (2011). "Cytotoxic effects of the trifunctional bispecific antibody FBTA05 in ex-vivo cells of chronic lymphocytic leukaemia depend on immune-mediated mechanisms". Anti-Cancer Drugs. 12 (10): 3085–3091. doi:10.1097/CAD.0b013e328344887f. PMID 21637160. S2CID 29327089.
  72. ^ Clinical trial number NCT00883896 for "Study to Evaluate the Safety and Efficacy of ILV-094 in Subjects With Rheumatoid Arthritis" at ClinicalTrials.gov
  73. ^ Clinical trial number NCT00563524 for "Study Evaluating the Safety and Tolerability of ILV-094 in Subjects With Psoriasis" at ClinicalTrials.gov
  74. ^ a b World Health Organization (2015). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 113" (PDF). WHO Drug Information. 29 (2). Archived (PDF) from the original on 4 November 2021. Retrieved 5 October 2020.
  75. ^ a b c d World Health Organization (2011). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 103" (PDF). WHO Drug Information. Archived (PDF) from the original on 15 July 2020. Retrieved 23 January 2020.
  76. ^ a b World Health Organization (2017). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 78". WHO Drug Information. 31 (3). hdl:10665/330961.
  77. ^ a b c "FDA Approves Novel Treatment to Control Pain in Cats with Osteoarthritis, First Monoclonal Antibody Drug for Use in Any Animal Species". U.S. Food and Drug Administration (FDA) (Press release). 13 January 2022. Archived from the original on 13 January 2022. Retrieved 14 January 2022. Public Domain This article incorporates text from this source, which is in the public domain.
  78. ^ "Prometheus Obtains Exclusive US Commercialization Rights for RENCAREX®" (Press release). Archived from the original on 7 July 2017. Retrieved 2 May 2011.
  79. ^ NCI Drug Dictionary: Glemtumumab vedotin Archived 5 April 2015 at the Wayback Machine
  80. ^ a b c "FDA approves Roche's Columvi, the first and only bispecific antibody with a fixed-duration treatment for people with relapsed or refractory diffuse large B-cell lymphoma" (Press release). F. Hoffmann-La Roche Ltd. 16 June 2023. Retrieved 16 June 2023 – via GlobeNewswire.
  81. ^ "Results from Cure Brain Cancer Foundation-funded trial show promise". www.curebraincancer.org.au. Archived from the original on 19 March 2020. Retrieved 14 June 2019.
  82. ^ "Uplizna- inebilizumab injection". DailyMed. 8 July 2019. Archived from the original on 13 June 2020. Retrieved 13 June 2020.
  83. ^ Clinical trial number NCT00537381 for "A Study of the Safety and Effectiveness of CNTO 95 in Patients With Metastatic Hormone Refractory Prostate Cancer" at ClinicalTrials.gov
  84. ^ Clinical trial number NCT00246012 for "A Study of the Safety and Efficacy CNTO 95 in Subjects With Advanced Melanoma" at ClinicalTrials.gov
  85. ^ a b c World Health Organization (2020). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 84". WHO Drug Information. 34 (3). hdl:10665/340680.
  86. ^ "FDA Grants Accelerated Approval for Alzheimer's Disease Treatment". U.S. Food and Drug Administration (FDA) (Press release). 6 January 2023. Archived from the original on 7 January 2023. Retrieved 7 January 2023.
  87. ^ a b c d World Health Organization (2018). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 79". WHO Drug Information. 32 (1). hdl:10665/330941.
  88. ^ a b Guthrie, Arlo (27 June 2017). "Zoetis launches breakthrough treatment for canine atopic dermatitis". VetNurse News. Archived from the original on 7 July 2018. Retrieved 6 July 2018.
  89. ^ "Margenza: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Archived from the original on 23 March 2021. Retrieved 17 December 2020.
  90. ^ "FDA Approves New Treatment for Hemophilia A or B". U.S. Food and Drug Administration (Press release). 1 October 2024. Retrieved 11 October 2024.
  91. ^ "U.S. FDA Approves Pfizer's Hympavzi (marstacimab-hncq) for the Treatment of Adults and Adolescents with Hemophilia A or B Without Inhibitors" (Press release). Pfizer. 11 October 2024. Retrieved 12 October 2024 – via Business Wire.
  92. ^ "FDA grants accelerated approval to mirvetuximab soravtansine-gynx for FRα positive, platinum-resistant epithelial ovarian, fallopian tube, or peritoneal cancer". U.S. Food and Drug Administration (FDA). 14 November 2022. Archived from the original on 18 November 2022. Retrieved 18 November 2022.
  93. ^ a b World Health Organization (1998). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 79" (PDF). WHO Drug Information. 12 (2). Archived (PDF) from the original on 15 July 2020. Retrieved 23 January 2020.
  94. ^ "FDA grants accelerated approval to mosunetuzumab-axgb". U.S. Food and Drug Administration. 22 December 2022. Archived from the original on 4 January 2023. Retrieved 3 January 2023.
  95. ^ Wilde, Michelle I.; Goa, Karen L. (1 May 1996). "Muromonab CD3". Drugs. 51 (5): 865–894. doi:10.2165/00003495-199651050-00010. ISSN 1179-1950. PMID 8861551. S2CID 13220985.
  96. ^ Hooks, M. A.; Wade, C. S.; Millikan, W. J. (1991). "Muromonab CD-3: a review of its pharmacology, pharmacokinetics, and clinical use in transplantation". Pharmacotherapy. 11 (1): 26–37. doi:10.1002/j.1875-9114.1991.tb03595.x. ISSN 0277-0008. PMID 1902291. Archived from the original on 10 September 2021. Retrieved 10 September 2021.
  97. ^ World Health Organization (2006). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 96" (PDF). WHO Drug Information. 20 (4). Archived (PDF) from the original on 15 July 2020. Retrieved 23 January 2020.
  98. ^ a b c d e f World Health Organization (2008). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 100 (prepublication copy)" (PDF). WHO Drug Information. Archived (PDF) from the original on 29 August 2021. Retrieved 5 October 2020.
  99. ^ Ruzicka, Thomas; Hanifin, Jon M.; Furue, Masutaka; Pulka, Grazyna; Mlynarczyk, Izabela; Wollenberg, Andreas; Galus, Ryszard; Etoh, Takafumi; Mihara, Ryosuke; Yoshida, Hiroki; Stewart, Jonathan; Kabashima, Kenji; XCIMA Study Group (2017). "Anti–Interleukin-31 Receptor a Antibody for Atopic Dermatitis". New England Journal of Medicine. 376 (9): 826–835. doi:10.1056/NEJMoa1606490. PMID 28249150. S2CID 205100502.
  100. ^ "Efleira (netakimab) Solution for Subcutaneous Use. Full Prescribing Information". Russian State Register of Medicines (in Russian). JSC Biocad. Retrieved 28 January 2024.
  101. ^ a b c d World Health Organization (2006). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 56" (PDF). WHO Drug Information. 20 (3). Archived (PDF) from the original on 15 July 2020. Retrieved 23 January 2020.
  102. ^ a b World Health Organization (2006). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 95" (PDF). WHO Drug Information. 20 (2). Archived (PDF) from the original on 15 July 2020. Retrieved 23 January 2020.
  103. ^ a b "FDA approves Novartis Kesimpta (ofatumumab), the first and only self-administered, targeted B-cell therapy for patients with relapsing multiple sclerosis" (Press release). Novartis. 20 August 2020. Archived from the original on 24 September 2020. Retrieved 21 August 2020.
  104. ^ "Keytruda- pembrolizumab injection, powder, lyophilized, for solution Keytruda- pembrolizumab injection, solution". DailyMed. 17 September 2019. Archived from the original on 17 June 2020. Retrieved 10 January 2020.
  105. ^ a b World Health Organization (2024). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 91". WHO Drug Information. 38 (1). hdl:10665/378096.
  106. ^ "FDA Roundup: March 22, 2024". U.S. Food and Drug Administration (FDA). 22 March 2024. Retrieved 23 March 2024. Public Domain This article incorporates text from this source, which is in the public domain.
  107. ^ a b "Regkirona EPAR". European Medicines Agency. 10 November 2021. Archived from the original on 12 November 2021. Retrieved 12 November 2021.
  108. ^ "ZYNYZ™ (retifanlimab-dlwr) injection, for intravenous use" (PDF). Archived (PDF) from the original on 23 March 2023. Retrieved 23 March 2023.
  109. ^ "Rituxan- rituximab injection, solution". DailyMed. 6 November 2019. Archived from the original on 4 August 2020. Retrieved 2 February 2020.
  110. ^ "UCB announces U.S. FDA approval of Rystiggo (rozanolixizumab-noli) for the treatment of adults with generalized myasthenia gravis" (Press release). UCB. 27 June 2023. Retrieved 28 June 2023 – via PR Newswire.
  111. ^ "Trodelvy- sacituzumab govitecan powder, for solution". DailyMed. Archived from the original on 20 March 2021. Retrieved 9 April 2021.
  112. ^ Xie, B.; Shen, J.; Dong, A.; Rashid, A.; Stoller, G.; Campochiaro, P. A. (2009). "Blockade of Sphingosine-1-phosphate Reduces Macrophage Influx and Retinal and Choroidal Neovascularization". Journal of Cellular Physiology. 218 (1): 192–198. doi:10.1002/jcp.21588. PMC 2905312. PMID 18781584.
  113. ^ "AusPAR: Sotrovimab". Therapeutic Goods Administration (TGA). 20 August 2021. Archived from the original on 1 November 2021. Retrieved 4 September 2021.
  114. ^ "Xevudy EPAR". European Medicines Agency (EMA). 15 December 2021. Archived from the original on 18 December 2021. Retrieved 17 December 2021.
  115. ^ a b c d "FDA grants accelerated approval to tarlatamab-dlle for extensive stage small cell lung cancer". U.S. Food and Drug Administration (FDA). 16 May 2024. Retrieved 17 May 2024. Public Domain This article incorporates text from this source, which is in the public domain.
  116. ^ "Janssen Marks First Approval Worldwide for Tecvayli (teclistamab) with EC Authorisation of First-in-Class Bispecific Antibody for the Treatment of Patients with Multiple Myeloma". Janssen Pharmaceutical Companies (Press release). 24 August 2022. Archived from the original on 26 October 2022. Retrieved 26 October 2022.
  117. ^ "U.S. FDA Approves Tecvayli (teclistamab-cqyv), the First Bispecific T-cell Engager Antibody for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma". Janssen Pharmaceutical Companies. 25 October 2022. Retrieved 26 October 2022.
  118. ^ Jostein Dahle; Ada H. V. Repetto-Llamazares; Camilla S. Mollatt; Katrine B. Melhus; Oyvind S. Bruland; Arne Kolstad; Roy H. Larsen (January 2013). "Evaluating antigen targeting and anti-tumor activity of a new anti-CD37 radioimmunoconjugate against non-Hodgkin's lymphoma". Anticancer Research. 33 (1): 85–95. PMID 23267131.
  119. ^ "Tezspire- tezepelumab-ekko injection, solution". DailyMed. 17 December 2021. Archived from the original on 25 December 2021. Retrieved 28 June 2022.
  120. ^ Wright, Rob (13 February 2018). "Seattle Genetics Legacy Of Partnering". Life Science Leader. Beyond The Printed Page. Archived from the original on 23 February 2018. Retrieved 22 February 2018.
  121. ^ "Enforcement Reports" (PDF). Archived (PDF) from the original on 21 September 2021. Retrieved 21 September 2021.
  122. ^ "RoActemra EPAR". European Medicines Agency. 17 September 2018. Archived from the original on 18 December 2021. Retrieved 18 December 2021.
  123. ^ World Health Organization (2010). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 64". WHO Drug Information. 24 (3). hdl:10665/74577.
  124. ^ a b "LEO Pharma announces FDA approval of Adbry tralokinumab". LEO Pharma (Press release). Archived from the original on 28 December 2021. Retrieved 28 December 2021.
  125. ^ Ruf, P; Jäger, M; Ellwart, J; Wosch, S; Kusterer, E; Lindhofer, H; et al. (2004). "Two new trifunctional antibodies for the therapy of human malignant melanoma". International Journal of Cancer. 108 (5): 725–732. doi:10.1002/ijc.11630. PMID 14696099. S2CID 25197165.
  126. ^ World Health Organization (2008). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 59". WHO Drug Information. 22 (1). hdl:10665/74120.
  127. ^ "Imjudo (tremelimumab) in combination with Imfinzi approved in the US for patients with unresectable liver cancer". AstraZeneca (Press release). 26 October 2022. Archived from the original on 24 October 2022. Retrieved 26 October 2022.
  128. ^ World Health Organization (2011). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 66". WHO Drug Information. 25 (3). hdl:10665/74683.
  129. ^ "Entyvio- vedolizumab injection, powder, lyophilized, for solution". DailyMed. 3 April 2020. Archived from the original on 21 October 2020. Retrieved 12 October 2020.
  130. ^ "FDA authorizes Gohibic (vilobelimab) injection for the treatment of COVID-19". U.S. Food and Drug Administration (FDA). 4 April 2023. Retrieved 4 April 2023.
  131. ^ a b "FDA grants accelerated approval to zanidatamab-hrii for previously treated unresectable or metastatic HER2-positive biliary tract cancer". U.S. Food and Drug Administration (FDA). 21 November 2024. Retrieved 23 November 2024.
  132. ^ a b "FDA grants accelerated approval to zenocutuzumab-zbco". U.S. Food and Drug Administration (FDA). 4 December 2024. Retrieved 5 December 2024.
  133. ^ "Astellas' Vyloy (zolbetuximab) Approved in Japan for Treatment of Gastric Cancer" (Press release). Astellas Pharma. 26 March 2024. Retrieved 19 April 2024 – via PR Newswire.
Retrieved from "http://en.wiki.x.io/w/index.php?title=List_of_therapeutic_monoclonal_antibodies&oldid=1263532616"